On Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray, Spravato (esketamine), to treat major depressive disorder. Oral antidepressants are the most common ...

Johnson & Johnson (J&J ... In January, 2025, J&J’s nasal spray Spravato secured a label expansion from the FDA for use as a single agent in adults with major depressive disorder (who were ...

The accelerating sales growth of Johnson & Johnson's Spravato could go up yet another gear after the FDA approved a third ... Spravato administered as a nasal spray achieved a rapid and ...

Payment options are available based on insurance coverage. The FDA has approved neffy 1 mg epinephrine nasal spray for treating anaphylaxis and other type 1 allergic reactions in children aged 4 ...

The U.S. Food and Drug Administration approved the expanded use of ARS Pharmaceuticals' nasal spray for severe allergic reactions in patients who weigh between 15 and 30 kilograms, the company said on ...

Milestone Pharmaceuticals Inc. announced that the FDA has ... for its nasal spray CARDAMYST™ (etripamil), aimed at treating Paroxysmal Supraventricular Tachycardia (PSVT). If approved, Milestone ...

FDA approves Neffy 1 mg for children aged 4+ weighing 15 to <30 kg for allergic reactions. Most insured patients can access Neffy for $25, while cash price is $199 for two doses. Feel unsure about ...

The FDA has approved Johnson & Johnson’s (J&J) Tremfya (guselkumab) for the treatment of moderately to severely active Crohn disease (CD). The regulatory action makes Tremfya the first and only ...

FDA approved Johnson & Johnson’s Tremfya as the first IL-23 inhibitor with both SC and IV induction options for Crohn’s disease. Tremfya sales reached $3.67 billion in 2024, marking a 17% year ...

On Thursday, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson’s (NYSE JNJ) Tremfya (guselkumab), the first and only IL-23 inhibitor offering subcutaneous (SC) and intravenous (IV ...